Advancing a Novel Target Critical to ECM Degradation


While at the Institute of Molecular and Cell Biology (IMCB), at the Agency for Science, Technology and Research (A*STAR), Albatroz co-founder and CEO, Dr. Fredric Bard discovered a pathway that controls protein glycosylation and drives extracellular matrix (ECM) degradation. This led to the discovery of a new target, which becomes selectively exposed at the cell surface during tumorigenesis.

In 2021, he teamed up with serial entrepreneur, Guy Heathers, to found Albatroz and accelerate this research. The company is on a mission to treat solid tumors and arthritic disorders that depend on ECM remodeling.

Today, Albatroz is the first company in the world developing therapeutic antibodies against Calnexin, the driver of ECM degradation, which is crucial to the growth and metastasis of a wide range of solid tumors and cartilage breakdown in arthritic joints.

The company has exclusive IP rights over the target, a broad range of therapeutic antibodies, and a broad range of in vitro and in vivo technologies in the field.




Inspired by the Albatross

Like an Albatross that flies where other birds do not, Albatroz Therapeutics is developing therapeutic antibodies against truly novel targets and has set its sight on new horizons targeting tissue remodeling.

Our mission is to address some of the toughest challenges in human health – beginning with cancer and arthritis.

The Albatroz Team


Frederic Bard

​CEO & Scientific Co-Founder

Guy Heathers

​CBO & Business Co-Founder

Cheng-I Wang

Head of Antibody Development